The Journal of Practical Medicine >
The mechanism of JUP promoting the malignant progression of high⁃grade serous ovarian cancer
Received date: 2025-07-03
Online published: 2025-12-25
Objective To investigate the role of junction plakoglobin (JUP) in high-grade serous ovarian cancer (HGSOC) and its influence on SET domain bifurcated 1 (SETDB1). Methods Human HGSOC cell lines with stable JUP overexpression or knockdown were established. The impact of JUP on cell proliferation, invasion, and migration was evaluated in vitro using colony formation, Transwell invasion, and wound healing assays. A subcutaneous xenograft model in nude mice was generated to dynamically monitor tumor growth and peritoneal nodule development, thereby elucidating the role of JUP in tumoral proliferation and metastasis. Co-immunoprecipitation (Co-IP) assays were performed to identify downstream molecules regulated by JUP. RT-qPCR, Western blotting, and histone methyltransferase activity assays were utilized to validate the influence of JUP on SETDB1 expression and enzymatic activity. Furthermore, rescue experiments were conducted to assess whether reconstitution of SETDB1 could reverse the malignant phenotypes induced by JUP knockdown in HGSOC cells. Results JUP was significantly overexpressed in high-grade serous ovarian cancer (HGSOC) tissues (P < 0.000 1), and patients with elevated JUP expression exhibited a poorer prognosis (P < 0.05). In vitro experiments demonstrated that JUP overexpression enhanced tumor cell proliferation, invasion, and migration, whereas JUP knockdown suppressed these malignant phenotypes (P < 0.01). In vivo studies further confirmed that JUP promoted tumor growth and peritoneal metastasis. Mechanistic analyses revealed that JUP directly interacts with SETDB1 and enhances its methyltransferase activity; notably, the oncogenic effects induced by JUP overexpression were reversed upon SETDB1 knockdown (P < 0.05). Conclusion JUP promotes the malignant progression of HGSOC by directly binding to and modulating the enzymatic activity of SETDB1, highlighting its potential as a therapeutic target for HGSOC.
Key words: high-grade serous ovarian cancer; JUP; SETDB1; proliferation; metastasis
Yutang HUANG , Weiqin DU , Dong YUAN , Tiantian LEI , Chunjie WEN , Lanxiang. WU . The mechanism of JUP promoting the malignant progression of high⁃grade serous ovarian cancer[J]. The Journal of Practical Medicine, 2025 , 41(24) : 3848 -3859 . DOI: 10.3969/j.issn.1006-5725.2025.24.008
| [1] | SIEGEL R L, KRATZER T B, GIAQUINTO A N, et al. Cancer statistics, 2025[J]. CA Cancer J Clin, 2025, 75(1): 10-45. doi:10.3322/caac.21871 |
| [2] | CARUSO G, WEROHA S J, CLIBY W. Ovarian Cancer: A Review[J]. JAMA, 2025, 334(14): 1278-1291. doi:10.1001/jama.2025.9495 |
| [3] | SANTORO A, ANGELICO G, TRAVAGLINO A, et al. The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features[J]. Crit Rev Oncol Hematol, 2025, 208: 104603. doi:10.1016/j.critrevonc.2024.104603 |
| [4] | DENG M, YANG R, JIANG J, et al. The silent spread: Exploring diverse metastatic pathways in high-grade serous ovarian cancer[J]. Front Med (Lausanne), 2025, 12: 1539024. doi:10.3389/fmed.2025.1539024 |
| [5] | FU R, HU R, LI W, et al. Unveiling drug resistance pathways in high-grade serous ovarian cancer (HGSOC): Recent advances and future perspectives[J]. Front Immunol, 2025, 16: 1556377. doi:10.3389/fimmu.2025.1556377 |
| [6] | KORDOWITZKI P, LANGE B, ELIAS K M, et al. Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer[J]. CA Cancer J Clin, 2025, 75(5): 436-460. doi:10.3322/caac.70008 |
| [7] | GAILLARD S, LACCHETTI C, ARMSTRONG D K, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update[J]. J Clin Oncol, 2025, 43(7): 868-891. doi:10.1200/op-24-00999 |
| [8] | POLAJZER S, CERNE K. Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance[J]. Int J Mol Sci, 2025, 26(6): 2545. doi:10.3390/ijms26062545 |
| [9] | DIAS M P, MOSER S C, GANESAN S, et al. Understanding and overcoming resistance to PARP inhibitors in cancer therapy[J]. Nat Rev Clin Oncol, 2021, 18(12): 773-791. doi:10.1038/s41571-021-00532-x |
| [10] | GUPTA R, KUMAR R, PENN C A, et al. Immune evasion in ovarian cancer: Implications for immunotherapy and emerging treatments[J]. Trends Immunol, 2025, 46(2): 166-181. doi:10.1016/j.it.2024.12.006 |
| [11] | WANG J, DEAN D C, HORNICEK F J, et al. RNA sequencing (RNA-Seq) and its application in ovarian cancer[J]. Gynecol Oncol, 2019, 152(1): 194-201. doi:10.1016/j.ygyno.2018.10.002 |
| [12] | 何婉珊, 洪小山, 陈冠桥, 等. 基于转录组测序技术筛选NSUN2在卵巢癌细胞的基因差异表达[J]. 实用医学杂志, 2023, 39(9): 1079-1085. |
| [13] | LI J, SWOPE D, RAESS N, et al. Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of beta-catenin signaling[J]. Mol Cell Biol, 2011, 31(6): 1134-1144. doi:10.1128/mcb.01025-10 |
| [14] | DING W, SUN J, SONG S, et al. Junction Plakoglobin - A Dual-Role Player in Cancer Biology[J]. Int J Surg, 2025, 111(6): 3920-3930. doi:10.1097/js9.0000000000002365 |
| [15] | CHEN K, ZENG J, SUN Y, et al. Junction plakoglobin regulates and destabilizes HIF2alpha to inhibit tumorigenesis of renal cell carcinoma[J]. Cancer Commun (Lond), 2021, 41(4): 316-332. doi:10.1002/cac2.12142 |
| [16] | WANG Z, HU J, CHEN J, et al. ICAT promotes colorectal cancer metastasis via binding to JUP and activating the NF-kappaB signaling pathway[J]. J Clin Lab Anal, 2022, 36(10): e24678. doi:10.1002/jcla.24678 |
| [17] | LHEUREUX S, GOURLEY C, VERGOTE I, et al. Epithelial ovarian cancer[J]. Lancet, 2019, 393(10177): 1240-1253. doi:10.1016/s0140-6736(18)32552-2 |
| [18] | LIU J F, KONSTANTINOPOULOS P A, MATULONIS U A. PARP inhibitors in ovarian cancer: Current status and future promise[J]. Gynecol Oncol, 2014, 133(2): 362-369. doi:10.1016/j.ygyno.2014.02.039 |
| [19] | 黄山高, 吴月玲, 张颖. 瞄准未来:卵巢癌靶向治疗的新进展[J]. 实用医学杂志, 2024, 40(14): 1901-1907. |
| [20] | DENG X, SHEN A, JIANG L. Bioinformatics analysis of JUP in patients with acute myocardial infarction and its potential application in clinical prognostic evaluation[J]. Front Cardiovasc Med, 2025, 12: 1531309. doi:10.3389/fcvm.2025.1531309 |
| [21] | VAHIDNEZHAD H, YOUSSEFIAN L, FAGHANKHANI M, et al. Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility[J]. Sci Rep, 2020, 10(1): 21622. doi:10.1038/s41598-020-78344-9 |
| [22] | YANG L, HUANG W, BAI X, et al. Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling[J]. Cell Death Dis, 2023, 14(6): 363. doi:10.1038/s41419-023-05882-1 |
| [23] | XIA J, MA N, SHI Q, et al. XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis[J]. J Cell Biol, 2024, 223(2): e202303015. doi:10.1083/jcb.202303015 |
| [24] | CHEN Y, YANG L, QIN Y, et al. Effects of differential distributed-JUP on the malignancy of gastric cancer[J]. J Adv Res, 2021, 28: 195-208. doi:10.1016/j.jare.2020.06.026 |
| [25] | HU J, HUANG R, LIANG C, et al. TRIM50 Inhibits Gastric Cancer Progression by Regulating the Ubiquitination and Nuclear Translocation of JUP[J]. Mol Cancer Res, 2023, 21(10): 1107-1119. doi:10.1158/1541-7786.mcr-23-0113 |
| [26] | KANG Y K. SETDB1 in Early Embryos and Embryonic Stem Cells[J]. Curr Issues Mol Biol, 2015, 17: 1-10. doi:10.21775/cimb.017.001 |
| [27] | MARKOULI M, STREPKOS D, PIPERI C. Structure, Activity and Function of the SETDB1 Protein Methyltransferase[J]. Life (Basel), 2021, 11(8): 817. doi:10.3390/life11080817 |
| [28] | LUO H, WU X, ZHU X H, et al. The functions of SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) in biological process and disease[J]. Epigenetics Chromatin, 2023, 16(1): 47. doi:10.1186/s13072-023-00519-1 |
| [29] | LAZARO-CAMP V J, SALARI K, MENG X, et al. SETDB1 in cancer: Overexpression and its therapeutic implications[J]. Am J Cancer Res, 2021, 11(5): 1803-1827. |
| [30] | WANG W, WANG J, ZHANG X, et al. Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer[J]. Onco Targets Ther, 2019, 12: 7451-7457. doi:10.2147/ott.s220700 |
| [31] | YANG H, SUI L, CAI C, et al. SETDB1 promotes progression through upregulation of SF3B4 expression and regulates the immunity in ovarian cancer[J]. J Ovarian Res, 2024, 17(1): 34. doi:10.1186/s13048-024-01358-8 |
| [32] | STREPKOS D, MARKOULI M, KLONOU A, et al. Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential[J]. Cancer Res, 2021, 81(3): 525-534. doi:10.1158/0008-5472.can-20-2906 |
/
| 〈 |
|
〉 |